Forms of apremilast
The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.
1. Apremilast Form H, wherein:
Form H is characterized by having 2 or more X-ray powder diffraction peaks selected from about 14.02, 19.41, 20.81 and 29.01 °2θ.
2. Apremilast Form H, according to claim 1 , wherein:
Form H has an X-ray powder diffraction pattern substantially as shown in FIG. 1 .
3. Apremilast Form H, wherein:
Form H is characterized by having 2 or more X-ray powder diffraction peaks selected from about 6.311, 4.570, 4.266 and 3.076 Angstroms.
4. Apremilast Form H according to claim 1 , wherein, as measured by differential scanning calorimetry:
Form H is characterized by an endothermic event at about 113° C.
5. Apremilast Form H according to claim 1 , wherein:
Form H is characterized by a differential scanning calorimetry pattern substantially as shown in FIG. 7 .
6. A composition comprising apremilast Form H according to claim 1 .
7. The composition according to claim 6 , wherein the composition is a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.
8. A method of treating psoriatic arthritis and psoriasis comprising administering a pharmaceutical formulation according to claim 7 to a subject in need thereof.
9. A method of making apremilast Form H according to claim 1 , comprising exposing a starting material comprising apremilast to dimethylformamide and water to yield apremilast Form H.
10. A method of making apremilast Form H according to claim 1 , comprising exposing a starting material comprising apremilast to dimethylformamide and tert-butyl methyl ether to yield apremilast Form H.